— Presentation on Wednesday, January 10, 2018, at 7:30 a.m. Pacific
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 3, 2018--
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a
company overview at the 36th Annual J.P. Morgan Healthcare Conference in
San Francisco on Wednesday, January 10, 2018, at 7:30 a.m. Pacific Time.
A breakout session will immediately follow the presentation.
A live audio webcast of the presentation and breakout session will be
accessible from the Investor Relations section of the Aimmune website at www.aimmune.com.
A replay of the webcast will be available at www.aimmune.com
for at least 30 days following the webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of protection
by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational biologic product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age and is currently being
evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by
the U.S. Food and Drug Administration (FDA) or the European Medicines
Agency (EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180103005369/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.